The observational study conducted by the Abramson Cancer Center at Penn Medicine aims to assess the cardiovascular effects of CART cell therapy in adults with CD19+ malignancies. Given the increasing adoption of CAR T-cell therapies in oncology, understanding the associated cardiovascular risks is critical for patient management and could influence treatment protocols. The findings may provide valuable insights for pharmaceutical companies developing CAR T-cell therapies, as they may need to address potential cardiotoxicity in their product labeling and risk management strategies. Furthermore, this study could position the sponsoring institution as a leader in cardio-oncology, potentially enhancing collaborations with biotech firms focused on CAR T-cell innovations.